![]() At the beginning of the second quarter Co-Diagnostics received emergency use authorization from the FDA for our Logix Smart COVID-19 test. Hello, everyone and thank you for joining us on the call. I'll now turn the time over to Dwight H Egan, CEO of Co-Diagnostics. We refer you to the company's earnings release out certainly before this call which contains reconciliation to the non-GAAP financial measures presented to their most comparable GAAP results. These non-GAAP financial measures should not be considered a replacement for and should be read together with GAAP results. In addition, the company will discuss certain non-GAAP financial measures during today's call. Co-Diagnostics assumes no obligation and expressly disclaims any duty to update any forward-looking statements to reflect events or circumstances occurring after this call or to reflect the occurrence of unanticipated events. Important factors which could cause actual results to differ materially from those in these forward-looking statements are detail Co-Diagnostics filings with the SEC. However, these statements are not guarantees or performance and may involve known and unknown risks and uncertainties that may cause the actual results to be materially different from any future results expressed or implied by such statements. The company believes these statements are based on reasonable assumptions. For example, statements concerning 2020 financial operational guidance, the development and regulatory clearance, commercialization and features of new products, plans and objectives of management and market trends are all forward-looking statements. In these statement of our company expectations, beliefs, plans, objectives, assumptions of future events or performance our forward-looking statements. Before we begin, we would like to inform the listeners that certain statements made by Co-Diagnostics during the course of this call may constitute forward-looking statements. And thank you everybody for joining us today. Please also note today's event is being recorded.Īt this time, I'd like to turn the conference call over to Andrew Benson. All participants are currently in a listen only mode. Good afternoon, everyone, and welcome to the Co-Diagnostics Q2 2020 Earnings Conference Call. Theodore O'Neill - Litchfield Hills Research ( NASDAQ: CODX) Q2 2020 Earnings Conference Call Aug4:30 PM ET NASDAQ does not use this value to determine compliance with the listing requirements.Co-Diagnostics Inc. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). ![]() It does not include securities convertible into the common equity securities. Market Cap (Capitalization) is a measure of the estimated value of the common equity securities of the company or their equivalent. Register for your free account today at. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |